Results 11 to 20 of about 9,980 (152)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background: There is renewed interest in repurposing β-lactam antibiotics for treatment of tuberculosis (TB). We investigated efficacy of cefdinir, that withstand the β-lactamase enzyme present in many bacteria, against drug-susceptible and multi-drug ...
Shashikant Srivastava, Shashikant Srivastava, Tania Thomas, Dave Howe, Lesibana Malinga, Prithvi Raj, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Tawanda Gumbo, Tawanda Gumbo   +10 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

Ceftazidime-avibactam

Revista Española de Quimioterapia, 2022
The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire   +2 more sources

Increased gene expression and copy number of mutated bla KPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae

BMC Microbiology, 2021
Background Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla KPC. Results We report the mutated bla KPC is not the only mechanism
Lingxiao Sun, Haibo Li, Qi Wang, Yingmei Liu, Bin Cao   +4 more
doaj   +1 more source

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source

Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35

Microbiology Spectrum, 2023
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj   +1 more source

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases

Antibiotics, 2021
Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Carola Mauri, Alberto Enrico Maraolo, Stefano Di Bella, Francesco Luzzaro, Luigi Principe   +4 more
doaj   +1 more source

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Antibiotics, 2023
Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-β-lactamase (MBL)-positive strains, has led to limited treatment options ...
Denis Piérard, Elizabeth D. Hermsen, Michal Kantecki, Francis F. Arhin   +3 more
doaj   +1 more source